Council of Scientific and Industrial Research

Other

Arvind Kumar Srivastava

Anil Kumar Rastogi

Deepak Raina

Ram Pratap

Ramesh Chander

Nitya Anand

Ram Chandra Gupta

Omkar Prasad Asthana

Ram Raghubir

Ashok Kumar Khanna

Sukh Dev

Savita Srivastava

Ashim Ghatak

Rajesh Kumar

Anil Kumar Dwivedi

Anju Puri

Narinder Kumar Kapoor

Ramesh Chandra

Satyavan Singh

Swarn Nityanand

Satyawan Singh

Atul Goel

Sudhir Srivastava

Chandeshwar Nath

Raghwendra Pal

Padmanabhan Madhusudanan Kunnath

Bhawani Shankar Joshi

Raja Roy

Kartikay Pandey

Lakshmi Vijay

Brajendra Kumar Tripathi

Priti Tiwari

Mavurapu Satyanarayana

Gaurav Taneja

Neha Rahuja

Arun Kumar Rawat

Natasha Jaiswal

Akhilesh Kumar Tamrakar

Vijai Lakshmi

Ajet Saxena

Preeti Tiwari

Mahendra Nath Srivastava

Poonam Gupta

Narender Tadigoppula

Brijendra Kumar Tripathi

Alok Kumar Verma

Mukesh Srivastava

Amar Bahadur Singh

Himanshu Singh

The present invention relates to the development of novel substituted 4,5-dihydro-2H-benzo[e]indazole-9-carboxylates, which can be used as therapeutic agents for the treatment and prevention of metabolic disorders, and a process of preparing said novel compounds. More particularly, the present invention relates to substituted 4,5-dihydro-2H-benzo[e]indazole-9-carboxylates and their related compounds, processes for preparing the said compounds and to their use in the treatment of diabetes and related metabolic disorders.

[object Object]

A bioactive fraction obtained fromthat is useful for the treatment of diabetes and dyslipidemia. This fraction can be provided in a pharmaceutical composition that is useful as antidiabetic and antidyslipidemic agent, or can be used in a method of treating diabetes and dyslipidemia in a subject. Also, a process for the preparation of bioactive fraction from. Isomeric xyloccensins and the preparation of such compounds. Also, pharmaceutical compositions comprising a therapeutically effective amount of such isomeric xyloccensins optionally along with one or more pharmaceutically acceptable carriers, additives, lubricant and diluents and the use of such pharmaceutical compositions in a method for treating dyslipidemia.

Pharmaceutical composition for treatment of diabetes and dyslipidemia

The present invention provides appropriately substituted chalcones, such as, for example, represented by the structural formula as shown herein below Wherein R1, R2 and R3 are selected from the group consisting of H, OH, O-alkyl, O-phenyl and O-substituted phenyl; B represents Ar&#x2014;Z&#x2014;O or RO; where Z is an alkane having up to 5 carbon atoms; R is substituted propanol amino, wherein substituted amino groups are selected from the group consisting of t-butyl, n-butyl, i-butyl, i-propyl, 4-phenyl piperazine-1-yl, 4-(2-methoxyphenyl)-piperazin-1-yl and 3,4-dimethoxy phenethyl; and Ar is thiazolidine-dione methylene phenoxy. The compounds prepared have been demonstrated to exhibit significant antidiabetic effect in various animal models indicating potential for further exploitation.

Oxy substituted chalcones as antihyperglycemic and antidyslipidemic agents

The present invention provides novel substituted flavone derivatives which exhibit anti-hyperglycemic and antidyslipedemic activity. The invention also provides a method for controlling type II diabetes and associated hyperlipidemic conditions in a mammal by administering compound of the present invention and compositions containing these derivatives.

Oxy substituted flavones as antihyperglycemic and antidyslipidemic agents

The present invention provides a novel saponin tigogenin penta glycoside isolated from the aerial parts ofand a process for the isolation thereof as well as its use in anti-hyperglycemic and hypolipidemic activities.

The invention provides a method of using pregnadienones and pregnadienols represented by the structural formula (I) as shown herein belowWherein X&#x2550;OH or O or combination thereof and positioning of olefinic bonds are at 4(5); 5(6); 16(17); 17(20) or various combinations and said compounds containing at least one olefinic bond in or on their D-ring for the treatment of hyperlipidemic and hyperglycemic conditions in mammals, said method comprising administering an effective amount of the said compounds to the recipient mammals.

Method of treating hyperlipidemic and hyperglycemic conditions in mammals using pregnadienols and pregnadienones

Growing community of inventors

Lucknow, India

Arvind Kumar Srivastava